Celgene gains on Revlimid data

Celgene Corp. (NASDAQ:CELG) gained $5.33 (11%) to $55.95 on Friday after reporting that Revlimid lenalidomide as maintenance therapy following autologous stem cell transplantation met the primary endpoint of significantly improving time to disease progression vs. placebo in the Phase III CALGB-100104 trial to treat multiple myeloma. NIH's National Cancer Institute (NCI), which sponsored the trial, said Revlimid led to a 58% reduction in the risk of disease progression vs. placebo. ...